BMO Capital Upgrades Pfizer To Outperform

Analysts at BMO Capital upgraded Pfizer Inc. PFE from Market Perform to Outperform. The price target for Pfizer has been raised from $33 to $36. Pfizer shares have gained 5.40% over the past 52 weeks, while the S&P 500 index has surged 14.57% in the same period. Pfizer's shares fell 0.21% to $33.10 in pre-market trading.